DETERMINE-reduced- Dapagliflozin Effect on Exercise Capacity
An International, Multicenter, Parallel-group, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluation the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
The purpose of this study is to answer the question of whether dapagliflozin can increase exercise capacity in patients with heart failure.
Principal Investigator: Dr. Harry Colfer
Contact: Study coordinator
Phone (Main): 231-487-3116
IRB Number: 2019-00035
Current Trial Type: 03877237